Late in 2023 the Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity and a BMI of 30 or over with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity
Their compatibility with established pharmaceutical supply chains without the constraints of cold-chain logistics, injection training or medical-waste handling creates opportunities to broaden distribution through retail pharmacies and remote care pathways
Focus on compound movements with progressive overload
During your visit, we will review your health history, discuss your goals, and determine whether GLP-1 therapy is right for you
In the FIGHT study, the use of liraglutide was associated with an increased risk for rehospitalization for other cardiovascular reasons (HR 1.33
Researcher-First Approach: Their support team is extremely responsive and virtually always available through multiple channels
